Pfizer, BMS ink billion dollar deal
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Pfizer |
Bristol-Myers Squibb |
$1B deal |
Pfizer has agreed to pay $250 million up front and up to $750 million in milestones to partner with BMS on apixaban, a blood clot therapy that has demonstrated promising efficacy and could go on to become a successor for Coumadin. |
|
Peptech |
EvoGenics |
$156M acquisition |
Australia's Peptech is acquiring rival antibody therapeutics player EvoGenics in a cash/shares deal worth $156 million. |
|
BMS |
Isis Pharmaceuticals |
Development deal |
The companies collaborate on the discovery, development and commercialization of antisense drugs targeting the gene PCSK9 for cardiovascular disease. |
|
Genentech |
Sangamo BioSciences |
Research and licensing agreement |
Sangamo BioSciences will provide Genentech with its zinc finger DNA-binding protein technology along with ZFP nucleases to generate cell lines with characteristics for protein pharmaceutical production purposes. |